Anti-EHV-1 glycoprotein I/gI Polyclonal Antibody from ProteoGenix; catalogue ARO-A22291; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-EHV-1 glycoprotein I/gI Polyclonal Antibody is a highly specific and sensitive tool for detecting and studying Equine Herpesvirus 1 (EHV-1) infections. This polyclonal antibody is produced using advanced biotechnology techniques and has been extensively tested to ensure its high quality and reliability.
EHV-1 is a highly contagious virus that affects horses, causing respiratory and neurological symptoms. The virus primarily targets the respiratory and nervous systems, leading to severe respiratory disease, abortion, and neurological disorders. The glycoprotein I/gI is a major surface protein of EHV-1 and plays a critical role in virus entry and spread within the host.
The Anti-EHV-1 glycoprotein I/gI Polyclonal Antibody is specifically designed for use in various applications, including immunofluorescence, immunohistochemistry, and western blotting. It is ideal for both in vitro and in vivo studies, making it a versatile tool for researchers and veterinarians.
This polyclonal antibody has been extensively used in studies on EHV-1 pathogenesis, vaccine development, and antiviral drug discovery. It has also been used to detect and monitor EHV-1 infections in horses, providing valuable insights into the virus’s spread and epidemiology. Additionally, the antibody has been used to identify and characterize EHV-1 strains, aiding in the development of effective diagnostic methods.
With its high specificity and sensitivity, the Anti-EHV-1 glycoprotein I/gI Polyclonal Antibody is an essential tool for understanding and combating EHV-1 infections. Its use in various applications and experimental studies makes it a valuable asset for researchers and veterinarians working in the field of equine health.
In conclusion, if you are looking for a reliable and specific tool to study EHV-1 infections, the Anti-EHV-1 glycoprotein I/gI Polyclonal Antibody is your go-to solution. Its proven effectiveness and versatility in various applications make it a top choice for researchers and veterinarians. Order now and take the first step towards understanding and controlling EHV-1 infections in horses.
ProteoGenix catalogue number ARO-A22291. For research use only.
Target: envelope glycoprotein I; ORF73; Clonality: Polyclonal Antibody; Applications: ELISA, IHC.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| envelope glycoprotein I; ORF73 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
